Sector deep dive: biotech

Definition

Development-stage biotech is the equity market’s purest probability business: companies with no revenue, whose value is a portfolio of drug programs, each a chain of binary trials with published base rates (event-fda-approvals), funded by serial dilution until approval or failure. Standard fundamental analysis has almost no purchase — the analyzable objects are the pipeline’s probability-weighted value, the cash runway, and the catalyst calendar. This entry carries that replacement kit.

How it works / structure

• The valuation grammar (risk-adjusted NPV): each program = peak-sales estimate × probability of success (per-phase base rates — the BIO/QLS compilation, labeled industry data) × margin, discounted (fa-dcf-valuation in explicitly probabilistic form), summed across the pipeline plus cash; the market’s implied PoS (backed out from price) vs the base rate is where theses live.
• The funding treadmill (the sector’s second axis): burn rate vs cash = RUNWAY in quarters (fa-financial-statements reduced to one number); companies time raises to data — positive readouts are followed by offerings with documented regularity (event-secondary-offerings — the post-data pop financing window); runway under ~4 quarters without a catalyst is the documented dilution-spiral entry condition.
• The reading kit beyond financials: trial design literacy (endpoints, powering, control arms, interim analyses — where informed priors beat coin flips), insider/specialist ownership (the sector where sent-13f-holdings specialist funds carry documented information), partnership validation (pharma licensing deals as external diligence), and the FDA pathway map (accelerated approval, breakthrough designation — each with documented approval-rate and post-approval-obligation implications).
• Portfolio shape (engine-relevant): single-program companies are binaries (risk-fixed-fractional sized to the gap, not the ATR); diversified pipelines and the sector ETF trade the base rates instead of a coin; commercial-stage biotech reverts to ordinary pharma analysis.

When it applies

Any development-stage position (the kit IS the analysis — generic metrics produce nonsense); catalyst-calendar positioning (lens-event-catalyst at its purest); dilution-cycle screens (runway math is mechanical and predictive of issuance); specialist-signal reads (the documented information asymmetry makes 13F/insider data unusually meaningful here).

Risk profile & failure modes

• Binary sizing failure (the sector’s account destroyer): −60/80% overnight gaps are the normal failure mode, not the tail — every sizing rule in pillar 7 applies at gap severity.
• Base-rate neglect: single-study enthusiasm against per-phase failure rates is the documented retail error; priors first, story second.
• Runway blindness: the thesis can be right and the equity still diluted to irrelevance before the payoff — the funding path is part of every biotech thesis.
• Expertise asymmetry: trial interpretation is a specialist domain; the platform treats unmodeled readouts as unpriceable and says so rather than synthesizing false confidence.

Evidence & limits

The regulatory pathway is FDA-documented; success-rate base rates are industry compilations (labeled); the post-data financing pattern and dilution spirals are documented sector behavior. Peak-sales estimation is soft (labeled); rNPV outputs inherit every input’s uncertainty — the framework’s value is comparative and disciplinary, not precision.

Falsifiable-thesis examples

Illustrations only, not signals:

• “X’s price implies a Phase-3 probability of success below 30% vs a 55% base rate for its indication and design (implied-vs-base-rate thesis, sized as a binary)” — falsified by the readout.
• “Development-stage names with under 4 quarters of runway and no dated catalyst underperform the sector ETF over 6 months (dilution-treadmill screen)” — falsified by the cohort return.

Cross-references

• The event machinery: event-fda-approvals, lens-event-catalyst
• The valuation form: fa-dcf-valuation (probabilistic)
• The funding axis: event-secondary-offerings, fa-financial-statements
• The sizing doctrine: risk-fixed-fractional, risk-scenario-analysis